Design and pre-clinical evaluation of a universal HIV-1 vaccine
Sven Létourneau, Eung-Jun Im, Tumelo Mashishi, Choechoe Brereton, Anne Bridgeman, Hongbing Yang, Lucy Dorrell, Tao Dong, Bette Korber, Andrew J McMichael, Tomás Hanke, Sven Létourneau, Eung-Jun Im, Tumelo Mashishi, Choechoe Brereton, Anne Bridgeman, Hongbing Yang, Lucy Dorrell, Tao Dong, Bette Korber, Andrew J McMichael, Tomás Hanke
Abstract
Background: One of the big roadblocks in development of HIV-1/AIDS vaccines is the enormous diversity of HIV-1, which could limit the value of any HIV-1 vaccine candidate currently under test.
Methodology and findings: To address the HIV-1 variation, we designed a novel T cell immunogen, designated HIV(CONSV), by assembling the 14 most conserved regions of the HIV-1 proteome into one chimaeric protein. Each segment is a consensus sequence from one of the four major HIV-1 clades A, B, C and D, which alternate to ensure equal clade coverage. The gene coding for the HIV(CONSV) protein was inserted into the three most studied vaccine vectors, plasmid DNA, human adenovirus serotype 5 and modified vaccine virus Ankara (MVA), and induced HIV-1-specific T cell responses in mice. We also demonstrated that these conserved regions prime CD8(+) and CD4(+) T cell to highly conserved epitopes in humans and that these epitopes, although usually subdominant, generate memory T cells in patients during natural HIV-1 infection.
Significance: Therefore, this vaccine approach provides an attractive and testable alternative for overcoming the HIV-1 variability, while focusing T cell responses on regions of the virus that are less likely to mutate and escape. Furthermore, this approach has merit in the simplicity of design and delivery, requiring only a single immunogen to provide extensive coverage of global HIV-1 population diversity.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
References
- Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol. 2004;5:233–236.
- McMichael AJ. HIV vaccines. Annu Rev Immunol. 2006;24:227–255.
- Duerr A, Wasserheit JN, Corey L. HIV vaccines: new frontiers in vaccine development. Clin Infect Dis. 2006;43:500–511.
- Hanke T, McMichael AJ, Dorrell L. Clinical experience with plasmid DNA- and modified vaccinia vaccine Ankara (MVA)-vectored HIV-1 clade A vaccine inducing T cells. J Gen Virol. 2007;88:1–12.
- Gaschen B, Taylor J, Yusim K, Foley B, Gao F, et al. Diversity considerations in HIV-1 vaccine selection. Science. 2002;296:2354–2360.
- Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, et al. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull. 2001;58:19–42.
- Williamson C, Morris L, Maughan MF, Ping LH, Dryga SA, et al. Characterization and selection of HIV-1 subtype C isolates for use in vaccine development AIDS. Res Hum Retroviruses. 2003;19:133–144.
- Amara RR, Sharma S, Patel M, Smith JM, Chennareddi L, et al. Studies on the cross-clade and cross-species conservation of HIV-1 Gag-specific CD8 and CD4 T cell responses elicited by a clade B DNA/MVA vaccine in macaques. Virology. 2005;334:124–133.
- Betts MR, Krowka J, Santamaria C, Balsamo K, Gao F, et al. Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians. J Virol. 1997;71:8908–8911.
- Buseyne F, Chaix ML, Fleury B, Manigard O, Burgard M, et al. Cross-clade-specific cytotoxic T lymphocytes in HIV-1-infected children. Virology. 1998;250:316–324.
- Cao H, Kanki P, Sankale JL, Dieng-Sarr A, Mazzara GP, et al. Cytotoxic T lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development. J Virol. 1997;71:8615–8623.
- Ferrari G, Humphrey W, McElrath MJ, Excler JL, Duliege AM, et al. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci USA. 1997;94:1396–1401.
- Burrows SR, Silins SL, Moss DJ, Khanna R, Misko IS, et al. T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen. J Exp Med. 1995;182:1703–1715.
- Dorrell L, Dong T, Ogg GS, McAdam S, Anzala o, et al. Distinct recognition of clade A HIV-1 epitopes by cytotoxic T lymphocytes generated from donors infected in Africa. J Virol. 1999;73:1708–1714.
- Dorrell L, Willcox BE, Jones EY, Gillespie G, Njai H, et al. Cytotoxic T lymphocytes recognize structurally diverse, clade-specific and cross-reactive peptides in human immunodeficiency virus type-1 gag through HLA-B53. Eur J Immunol. 2001;31:1747–1756.
- Gotch F, McMichael A, Rothbard J. Recognition of influenza A matrix protein by HLA-A2-restricted cytotoxic T lymphocytes. Use of analogues to orientate the matrix peptide in the HLA-A2 binding site J Exp Med. 1988;168:2045–2057.
- Hausmann S, Biddison WE, Smith KJ, Ding YH, Garboczi DN, et al. Peptide recognition by two HLA-A2/Tax11-19-specific T cell clones in relationship to their MHC/peptide/TCR crystal structures. J Immunol. 1999;162:5389–5397.
- Larke N, Im E-J, Wagner R, Williamson C, Williamson A-L, et al. Combined single-clade candidate HIV-1 vaccines induce T cell responses limited by multiple forms of in vivo immune interference. Eur J Immunol. 2007;37:566–577.
- Lee JK, Stewart-Jones G, Dong T, Harlos K, Di Gleria K, et al. T cell cross-reactivity and conformational changes during TCR engagement. J Exp Med. 2004;200:1455–1466.
- Goulder PJ, Watkins DI. HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol. 2004;4:630–640.
- Klenerman P, Wu Y, Phillips R. HIV: current opinion in escapology. Curr Opin Microbiol. 2002;5:408–413.
- Walker BD, Goulder PJ. AIDS. Escape from the immune system. Nature. 2000;407:313–314.
- McMichael A, Mwau M, Hanke T. HIV T cell vaccines, the importance of clades. Vaccine. 2002;20:1918–1921.
- Blay WM, Gnanakaran S, Foley B, Doria-Rose NA, Korber BT, et al. Consistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaques. J Virol. 2006;80:999–1014.
- Gao F, Korber BT, Weaver E, Liao HX, Hahn BH, et al. Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity. Expert Rev Vaccines. 2004;3:S161–168.
- Gao F, Weaver EA, Lu Z, Li Y, Liao HX, et al. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol. 2005;79:1154–1163.
- Kothe DL, Decker JM, Li Y, Weng Z, Bibollet-Ruche F, et al. Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology. 2007;360:218–234.
- Kothe DL, Li Y, Decker JM, Bibollet-Ruche F, Zammit KP, et al. Ancestral and consensus envelope immunogens for HIV-1 subtype C. Virology. 2006;352:438–449.
- Weaver EA, Lu Z, Camacho ZT, Moukdar F, Liao HX, et al. Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen. J Virol. 2006;80:6745–6756.
- Dorrell L, Yang H, Ondondo B, Dong T, di Gleria K, et al. Expansion and diversification of HIV-1-specific T cells following immunisation of HIV-1-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 gag vaccine. J Virol. 2006;80:4705–4716.
- Goonetilleke N, Moore S, Dally L, Winstone N, Mahmoud N, et al. Prime-boost vaccination with recombinant DNA and MVA expressing HIV-1 Clade A gag and immunodominant CTL epitopes induces multi-functional HIV-1-specific T cells in healthy subjects. J Virol. 2006;80:4717–4728.
- Slyker JA, Lohman BL, Mbori-Ngacha DA, Reilly M, Wee EG, et al. Modified vaccinia Ankara expressing HIVA antigen stimulates HIV-1-specific CD8 T cells in ELISpot assays of HIV-1 exposed infants. Vaccine. 2005;23:4711–4719.
- Altfeld M, Addo MM, Shankarappa R, Lee PK, Allen TM, et al. Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences. J Virol. 2003;77:7330–7340.
- Catanzaro AT, Koup RA, Roederer M, Bailer RT, Enama ME, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis. 2006;194:1638–1649.
- Graham BS, Koup RA, Roederer M, Bailer RT, Enama ME, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis. 2006;194:1650–1660.
- Seaman MS, Xu L, Beaudry K, Martin KL, Beddall MH, et al. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol. 2005;79:2956–2963.
- Bertoletti A, Sette A, Chisari FV, Penna A, Levrero M, et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic. T cells Nature. 1994;369:407–410.
- Klenerman P, Rowland-Jones S, McAdam S, Edwards J, Daenke S, et al. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. Nature. 1994;369:403–407.
- Basu D, Williams CB, Allen PM. In vivo antagonism of a T cell response by an endogenously expressed ligand. Proc Natl Acad Sci U S A. 1998;95:14332–14336.
- Gilbert SC, Plebanski M, Gupta S, Morris J, Cox M, et al. Association of malaria parasite population structure, HLA, and immunological antagonism. Science. 1998;279:1173–1177.
- Lau LL, Jiang J, Shen H. In vivo modulation of T cell responses and protective immunity by TCR antagonism during infection. J Immunol. 2005;174:7970–7976.
- Plebanski M, Lee EA, Hannan CM, Flanagan KL, Gilbert SC, et al. Altered peptide ligands narrow the repertoire of cellular immune responses by interfering with T-cell priming. Nat Med. 1999;5:565–571.
- Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med. 2007;13:100–106.
- Rolland M, Jensen MA, Nickle DC, Yan J, Learn GH, et al. Reconstruction and function of Ancestral Center-Of-Tree (COT) HIV-I Proteins J Virol. 2007
- Hanke T, Schneider J, Gilbert SC, Hill AVS, McMichael A. DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: Immunogenicity in mice. Vaccine. 1998;16:426–435.
- Nkolola JP, Wee EG-T, Im E-J, Jewell CP, Chen N, et al. Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa. Gene Ther. 2004;11:1068–1080.
- Allen TM, Sidney J, del Guercio M-F, Glickman RL, Lensmeyer GL, et al. Characterization of the peptide-binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from SIV. J Immunol. 1998;160:6062–6071.
- Hanke T, Szawlowski P, Randall RE. Construction of solid matrix-antibody-antigen complexes containing simian immunodeficiency virus p27 using tag-specific monoclonal antibody and tag-linked antigen. J-Gen-Virol. 1992;73:653–660.
- Takahashi H, Cohen J, Hosmalin A, Cease KB, Houghten R, et al. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility molecule-restricted murine cytotoxic T lymphocytes. Proc Natl Acad Sci USA. 1988;85:3105–3109.
- Andre S, Seed B, Eberle J, Schraut W, Bultmann A, et al. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol. 1998;72:1497–1503.
- Kozak M. An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res. 1987;15:8125–8148.
- Hanke T, McMichael AJ. Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat Med. 2000;6:951–955.
- Im E-J, Hanke T. Pre-clinical evaluation of candidate HIV type 1 vaccines in inbred strains and an outbred stock of mice. AIDS Res Hum Retroviruses. 2007;23:857–862.
- Hanke T, Blanchard TJ, Schneider J, Ogg GS, Tan R, et al. Immunogenicities of intravenous and intramuscular administrations of MVA-based multi-CTL epitope vaccine for HIV in mice. J Gen Virol. 1998;79:83–90.
- Kmieciak D, Bednarek I, Takiguchi M, Wasik TJ, Bratosiewicz J, et al. The effect of epitope variation on the profile of cytotoxic T lymphocyte responses to the HIV envelope glycoprotein. Int Immunol. 1998;10:1789–1799.
- Goulder PJ, Altfeld MA, Rosenberg ES, Nguyen T, Tang Y, et al. Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Exp Med. 2001;193:181–194.
- Frahm N, Kiepiela P, Adams S, Linde CH, Hewitt HS, et al. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol. 2006;7:173–178.
- Gallimore A, Dumrese T, Hengartner H, Zinkernagel RM, Rammensee HG. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J Exp Med. 1998;187:1647–1657.
- Makki A, Weidt G, Blachere NE, Lefrancois L, Srivastava PK. Immunization against a dominant tumor antigen abrogates immunogenicity of the tumor. Cancer Immun. 2002;2:4.
- Bhattacharya T, Daniels M, Heckerman D, Foley B, Frahm N, et al. Founder effects in the assessment of HIV polymorphisms and HLA allele associations. Science. 2007;315:1583–1586.
- Moore CB, John M, James IR, Christiansen FT, Witt CS, et al. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science. 2002;296:1439–1443.
- Streeck H, Lichterfeld M, Alter G, Meier A, Teigen N, et al. Recognition of a defined region within p24 Gag by CD8+ T cells during primary HIV-1 infection in individuals expressing protective HLA class I alleles J Virol. 2007
- Gilbert SC, Schneider J, Hannan CM, Hu JT, Plebanski M, et al. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine. 2002;20:1039–1045.
- Johnson RP, Hammond SA, Trocha A, Siliciano RF, Walker BD. Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine. J Virol. 1994;68:3145–3153.
- Johnson RP, Trocha A, Buchanan TM, Walker BD. Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation. J Exp Med. 1992;175:961–971.
- Johnson RP, Trocha A, Yang L, Mazzara GP, Panicali DL, et al. HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells. J Immunol. 1991;147:1512–1521.
- Harrer E, Harrer T, Barbosa P, Feinberg M, Johnson RP, et al. Recognition of the highly conserved YMDD region in the human immunodeficiency virus type 1 reverse transcriptase by HLA-A2-restricted cytotoxic T lymphocytes from an asymptomatic long-term nonprogressor. J Infect Dis. 1996;173:476–479.
- Johnson RP, Trocha A, Buchanan TM, Walker BD. Recognition of a highly conserved region of human immunodeficiency virus type 1 gp120 by an HLA-Cw4-restricted cytotoxic T-lymphocyte clone. J Virol. 1993;67:438–445.
- Rowland-Jones SL, Dong T, Fowke KR, Kimani J, Krausa P, et al. Cytotoxic T cell responses to multiple conserved epitopes in HIV-resistant prostitutes in Nairobi. J Clin Inv. 1998;102:1758–1765.
- Wilson CC, Palmer B, Southwood S, Sidney J, Higashimoto Y, et al. Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes. J Virol. 2001;75:4195–4207.
- Wilson CC, McKinney D, Anders M, MaWhinney S, Forster J, et al. Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to Multiple conserved epitopes in HIV-1. J Immunol. 2003;171:5611–5623.
- Ferrari G, Kostyu DD, Cox J, Dawson DV, Flores J, et al. Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines. AIDS Res Hum Retroviruses. 2000;16:1433–1443.
Source: PubMed